Patents Assigned to Vical Incorporated
  • Patent number: 9205146
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: December 8, 2015
    Assignees: Vical Incorporated, THE UNIVERSITY OF WASHINGTON
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 9180162
    Abstract: The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: November 10, 2015
    Assignee: Vical Incorporated
    Inventors: Gary G. Hermanson, Andrew J. Geall, Mary Kopke Wloch
  • Patent number: 9161973
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: October 20, 2015
    Assignees: Vical Incorporated, UNIVERSITY OF WASHINGTON
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 9102950
    Abstract: The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 11, 2015
    Assignee: Vical Incorporated
    Inventors: Jukka Hartikka, Sean M. Sullivan, Joel D. Enas, Alain P. Rolland
  • Patent number: 8999345
    Abstract: The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: April 7, 2015
    Assignee: Vical Incorporated
    Inventors: Jukka Hartikka, Sean M. Sullivan, Joel D. Enas, Alain Rolland
  • Publication number: 20150030631
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 29, 2015
    Applicants: VICAL INCORPORATED, The University of Washington
    Inventors: ADRIAN VILALTA, MICHAL MARGALITH, LICHUN DONG, DAVID M. KOELLE
  • Publication number: 20150010597
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2, VP11/12, and VP13/14 polypeptides.
    Type: Application
    Filed: September 17, 2014
    Publication date: January 8, 2015
    Applicants: Vical Incorporated, The University Of Washington
    Inventors: Adrian VILALTA, Michal Margalith, Lichun Dong, David M. Koelle
  • Publication number: 20150010596
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 8, 2015
    Applicants: Vical Incorporated, The University of Washington
    Inventors: Adrian VILALTA, Michal Margalith, Lichun Dong, David M. Koelle
  • Publication number: 20140370055
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 18, 2014
    Applicants: Vical Incorporated, THE UNIVERSITY OF WASHINGTON
    Inventors: Adrian VILALTA, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8852610
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: October 7, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Maragalith, Lichun Dong, David M. Koelle
  • Patent number: 8852611
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: October 7, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Maragalith, Lichun Dong, David M. Koelle
  • Patent number: 8840903
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2, VP11/12, and VP13/14 polypeptides.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: September 23, 2014
    Assignee: Vical Incorporated
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8840904
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV VP11/12 polypeptides.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 23, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8834894
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 16, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8828408
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV VP13/14 polypeptides.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 9, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8821890
    Abstract: The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: September 2, 2014
    Assignee: Vical Incorporated
    Inventors: Catherine J. Luke, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez
  • Publication number: 20140186382
    Abstract: The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 3, 2014
    Applicant: Vical Incorporated
    Inventors: Gary G. HERMANSON, Andrew J. Geall, Mary Kopke Wloch
  • Patent number: 8673317
    Abstract: The invention relates to plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens, which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of any of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods of inducing an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: March 18, 2014
    Assignee: Vical Incorporated
    Inventors: Gary G. Hermanson, Andrew J. Geall, Mary Kopke Wloch
  • Publication number: 20130273078
    Abstract: The present disclosure provides combinations of immunotherapeutics and methods for treating medical conditions that are characterized by the lack of an effective immune response, for example as would result following a down-regulation of MHC class I, such as in cancer. The immunotherapeutic compositions of the invention, which can be used to treat the medical conditions, include one or more immunostimulatory antibodies or molecules having specificity for CTLA-4, PD-1, PD-L1, PD-L2, CD40, OX40, CD137, GITR, ILT2, or ILT3, or ligands for these molecules (e.g., an isolated fully-human monoclonal antibody) in association with one or more alloantigens, such as, vector(s) capable of expressing protein(s) or peptide(s) that stimulate T-cell immunity against tissues or cells, formulated in a pharmaceutically acceptable carrier. The proteins or peptides may comprise class I major histocompatibility complex (MHC) antigens, ?2-microglobulins, or cytokines. The MHC antigen may be foreign to the subject.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 17, 2013
    Applicant: Vical Incorporated
    Inventor: Vical Incorporated
  • Patent number: 8541628
    Abstract: Cationic lipids having a derivatized quaternary ammonium head group that provide improved cell targeting ability and enhanced transfective efficacy for introducing molecules into cells are provided.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: September 24, 2013
    Assignee: Vical Incorporated
    Inventor: Carl J Wheeler